Therapy of early chronic phase chronic myelogenous leukemia (CML) with SCH54031 (PEG interferon alpha 2B/PEG intron) and low-dose cytosine arabinoside (Ara-C).

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 03 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

21 Nov 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center
06 Jun 2013 Planned End Date changed from 1 Jan 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
27 Aug 2012 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com